

<b>Reference:</b>	FOI.5356.21
<b>Subject:</b>	Anti-VEFG treatments for eye conditions
<b>Date of Request:</b>	15 February 2021

**Requested:**

1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Fluocinolone acetonide
  - Ranibizumab
  
2. Within your trust how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:
  - Aflibercept
  - Bevacizumab
  - Brolucizumab
  - Dexamethasone
  - Fluocinolone
  - Ranibizumab
  
3. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:

Wet Age Related Macular Degeneration (wAMD)

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

Diabetic Macular Oedema (DMO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

**Response:**

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, for the period September to December 2020, as requested.

<b>Treatment</b>	<b>Number of patients</b>
Aflibercept	592
Bevacizumab	0
Brolucizumab	0
Dexamethasone	12
Fluocinolone acetonide	*
Ranibizumab	1,113

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

2. The UHB provides, within the table below, the number of intra-vitreous injections/implants used for the listed treatments, for the period September to December 2020, as requested.

<b>Treatment</b>	<b>Number used</b>
Aflibercept	1,631
Bevacizumab	0
Brolucizumab	0
Dexamethasone	12
Fluocinolone	0
Ranibizumab	2,257

3. The UHB provides, within the table below, the number of intra-vitreous injections/implants used, by eye condition and treatments listed, for the period September to December 2020, as requested.

<b>Treatment</b>	<b>Wet Age Related Macular Degeneration</b>	<b>Diabetic Macular Oedema</b>	<b>Retinal Vein Occlusion</b>
Aflibercept	1,047	357	205
Bevacizumab	0	0	0
Brolucizumab	0	Not applicable	Not applicable
Dexamethasone	0	7	5
Ranibizumab	1,386	260	532

